RecruitingNCT06482554
Lumateperone or current medication for low motivation with schizophrenia
About this title
Read the official source — NCT06482554Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- ShreveportSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: June 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 80
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06482554
- Official title
Show the full official title
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Shreveport
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Louisiana State University Health Sciences Center Shreveport, a university.
Does this study involve medication?
Yes. The study involves medication, including Lumateperone 42 mg and Risperidone 2 mg.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
